{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:17:37Z","timestamp":1770988657199,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.heliyon.2022.e11782","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T12:05:43Z","timestamp":1669637143000},"page":"e11782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-7588","authenticated-orcid":false,"given":"Jona F.","family":"Houthuys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Wilmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-1403","authenticated-orcid":false,"given":"Marijke","family":"Peetermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Meersseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2022.e11782_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e11782_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00277-020-04311-z","article-title":"Low-dose ruxolitinib shows effective in treating myelofibrosis","volume":"100","author":"Yang","year":"2021","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.heliyon.2022.e11782_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2022.e11782_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11782_bib5","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.heliyon.2022.e11782_bib6","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.heliyon.2022.e11782_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"8","key":"10.1016\/j.heliyon.2022.e11782_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ajh.24775","article-title":"A\u00a0life-threatening ruxolitinib discontinuation syndrome","volume":"92","author":"Coltro","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2022.e11782_bib9","doi-asserted-by":"crossref","first-page":"23 8885","DOI":"10.3390\/ijms21238885","article-title":"The genetic basis of primary myelofibrosis and its clinical relevance","volume":"21","author":"Rumi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2022.e11782_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.heliyon.2022.e11782_bib11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428194.2020.1728752","article-title":"Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy","volume":"61","author":"Benevolo","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.heliyon.2022.e11782_bib12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11782_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e11782_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3960\/jslrt.18021","article-title":"Atraumatic splenic ruptures triggered both remission and death in a single case of blastic plasmacytoid dendritic cell neoplasm","volume":"59","author":"Daitoku","year":"2019","journal-title":"J.\u00a0Clin. Exp. Hematop.: JCEH"},{"issue":"21","key":"10.1016\/j.heliyon.2022.e11782_bib15","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.2014.117","article-title":"Progressive anemia and left upper quadrant pain in a patient with polycythemia vera","volume":"311","author":"Roberts","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2022.e11782_bib16","article-title":"Spontaneous splenic rupture: an unusual presentation of CML","volume":"2011 bcr0220113879","author":"Jafferbhoy","year":"2011","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e11782_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.surge.2015.08.001","article-title":"Blunt splenic trauma: assessment, management and outcomes","volume":"14","author":"El-Matbouly","year":"2016","journal-title":"Surgeon"},{"issue":"2","key":"10.1016\/j.heliyon.2022.e11782_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1148\/radiology.190.2.8284390","article-title":"Splenic enlargement in neonates during ECMO","volume":"190","author":"Klippenstein","year":"1994","journal-title":"Radiology"},{"issue":"3 FSO372","key":"10.1016\/j.heliyon.2022.e11782_bib19","article-title":"Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci. OA"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022030705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022030705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T13:51:30Z","timestamp":1767102690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022030705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2405844022030705"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11782","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e11782"}}